文献速递心脑血管急症重症综合管理与镇静镇痛

当前治疗干预对创伤性脑损伤脑血管反应性的有限影响:叙述性综述

The Limited Impact of Current Therapeutic Interventions on Cerebrovascular Reactivity in Traumatic Brain Injury: A Narrative Overview.
PubMed 文献 · Neurocrit Care · 2021-01-01
一句话结论中重度TBI后脑血管反应性受损与不良预后相关,现有ICP/CPP导向的指南治疗对其影响有限,需探索分子通路靶向治疗。

本文为叙述性综述,回顾成人中重度创伤性脑损伤(TBI)中脑血管反应性受损的已知驱动因素,并评估基于指南的ICP/CPP治疗策略对持续监测的脑血管反应性的影响。文献提示高龄、弥漫性损伤模式及持续ICP升高可能驱动反应性受损;现有ICP/CPP指南治疗对脑血管反应性影响有限,患者ICU期间大部分时间处于反应性受损状态。新兴治疗范式聚焦于基于脑血管反应性的个体化CPP和ICP阈值,但未直接靶向功能障碍通路。作者认为需进一步研究分子通路以开发预防和治疗脑血管反应性受损的疗法。

要点

  • 中重度TBI后脑血管反应性受损与不良预后相关,且可能在整个ICU住院期间主导生理紊乱格局。
  • 文献提示高龄、弥漫性损伤模式和持续ICP升高可能驱动脑血管反应性受损。
  • 现有基于ICP/CPP的指南治疗对脑血管反应性影响有限,患者大部分ICU时间处于反应性受损状态。
  • 新兴治疗范式聚焦于基于脑血管反应性的个体化CPP和ICP阈值,但未直接靶向功能障碍通路。
  • 作者认为需进一步研究分子通路,以开发针对脑血管反应性受损的预防和治疗药物。

适用人群与场景

  • 成人中重度创伤性脑损伤(TBI)患者,处于ICU治疗期间。

处置流程与药物剂量

  • 当前ICU治疗策略为基于指南的颅内压(ICP)和脑灌注压(CPP)导向治疗。
  • 新兴治疗范式聚焦于基于脑血管反应性设定个体化CPP和ICP阈值,但未直接靶向功能障碍通路。

研究设计与关键结果

  • 叙述性综述:文献提示高龄、弥漫性损伤模式和持续ICP升高可能驱动脑血管反应性受损。
  • 现有ICP/CPP指南治疗对脑血管反应性影响有限,患者大部分ICU期间处于反应性受损状态。

证据类型、等级与局限

  • 证据类型:叙述性综述。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 现有ICP/CPP导向的指南治疗对脑血管反应性影响有限,患者大部分ICU时间处于反应性受损状态。
  • 作者认为需进一步研究分子通路,以开发针对脑血管反应性受损的预防和治疗药物。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Current intensive care unit (ICU) treatment strategies for traumatic brain injury (TBI) care focus on intracranial pressure (ICP)- and cerebral perfusion pressure (CPP)-directed therapeutics, dictated by guidelines. Impaired cerebrovascular reactivity in moderate/severe TBI is emerging as a major associate with poor outcome and appears to dominate the landscape of physiologic derangement over the course of a patient's ICU stay. Within this article, we review the literature on the known drivers of impaired cerebrovascular reactivity in adult TBI, highlight the current knowledge surrounding the impact of guideline treatment strategies on continuously monitored cerebrovascular reactivity, and discuss current treatment paradigms for impaired reactivity. Finally, we touch on the areas of future research, as we strive to develop specific therapeutics for impaired cerebrovascular reactivity in TBI. There exists limited literature to suggest advanced age, intracranial injury patterns of diffuse injury, and sustained ICP elevations may drive impaired cerebrovascular reactivity. To date, the literature suggests there is a limited impact of such ICP/CPP guideline-based therapies on cerebrovascular reactivity, with large portions of a given patients ICU period spent with impaired cerebrovascular reactivity. Emerging treatment paradigms focus on the targeting individualized CPP and ICP thresholds based on cerebrovascular reactivity, without directly targeting the pathways involved in its dysfunction. Further work involved in uncovering the molecular pathways involved in impaired cerebrovascular reactivity is required, so that we can develop therapeutics directed at its prevention and treatment.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Froese L, Batson C, Gomez A, et al. The Limited Impact of Current Therapeutic Interventions on Cerebrovascular Reactivity in Traumatic Brain Injury: A Narrative Overview. Neurocrit Care. 2021. PMID: 32468328. doi:10.1007/s12028-020-01003-4

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。